A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment WithdrawalGiuseppe Floris, Patrick Schöffski, Agnieszka Woźniak et al.|Clinical Cancer Research|2012Cited by 69
Outcome after PORT in ypN2 or R1/R2 versus no PORT in ypN0 Stage III-N2 NSCLC after Induction Chemotherapy and ResectionCharlotte Billiet, Dirk De Ruysscher, Marc Hendrikx et al.|Journal of Thoracic Oncology|2016Cited by 25
Establishment, characterization and imaging of a first platinum-resistant penile cancer patient derived xenograft in nude mice: An eUROGEN projectMaarten Albersen, Lara Rizzotto, Uroš Milenković et al.|European Urology Open Science|2020Cited by 1
Supplementary Figure Legend from A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment WithdrawalGiuseppe Floris, Patrick Schöffski, Agnieszka Woźniak et al.|Unknown|2023Cited by 0
Supplementary Figure 2 from A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment WithdrawalGiuseppe Floris, Patrick Schöffski, Agnieszka Woźniak et al.|Unknown|2023Cited by 0